US 11,752,100 B2
Intranasal delivery of olanzapine by precision olfactory device
John D. Hoekman, Seattle, WA (US); Kelsey H. Satterly, Seattle, WA (US); Inna Dashevsky, Seattle, WA (US); and Aditya R. Das, Foster City, CA (US)
Assigned to Impel Pharmaceuticals Inc., Seattle, WA (US)
Filed by Impel Pharmaceuticals Inc., Seattle, WA (US)
Filed on Jan. 12, 2022, as Appl. No. 17/574,511.
Application 17/574,511 is a continuation of application No. 16/240,653, filed on Jan. 4, 2019, granted, now 11,278,492.
Claims priority of provisional application 62/776,414, filed on Dec. 6, 2018.
Claims priority of provisional application 62/774,088, filed on Nov. 30, 2018.
Claims priority of provisional application 62/614,324, filed on Jan. 5, 2018.
Prior Publication US 2022/0183965 A1, Jun. 16, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 31/5513 (2006.01); A61M 15/00 (2006.01); A61K 9/16 (2006.01); A61P 25/18 (2006.01); A61K 31/00 (2006.01)
CPC A61K 9/0043 (2013.01) [A61K 9/16 (2013.01); A61K 9/1617 (2013.01); A61K 9/1623 (2013.01); A61K 9/1652 (2013.01); A61K 31/00 (2013.01); A61K 31/5513 (2013.01); A61M 15/003 (2014.02); A61P 25/18 (2018.01)] 33 Claims
OG exemplary drawing
 
1. A method for acutely treating agitation in a human subject, comprising:
intranasally administering, using an intranasal delivery device, a single dose of a dry pharmaceutical composition comprising 2-20 mg of olanzapine as a single active ingredient to the subject exhibiting agitation, thereby reducing agitation within 30 minutes,
wherein the intranasal delivery device comprises a compound chamber containing the dry pharmaceutical composition and a separate propellant canister containing propellant;
wherein the propellant released from the canister contacts and propels dry pharmaceutical composition through a narrow, targeted delivery plume for intranasal delivery;
wherein the intranasal administration provides a shorter median Tmax compared to intramuscular or oral administration of the single dose of olanzapine, and
wherein the intranasal administration provides a mean peak plasma olanzapine concentration (Cmax) of at least 25 ng/ml.